CHICAGO–( COMPANY CORD)– Tempus AI, Inc. (NASDAQ: TEM), a modern technology business leading the fostering of AI to progress accuracy medication and individual treatment, today introduced that 18 abstracts, consisting of one public speaking, have actually been approved for discussion at the American Organization for Cancer Cells Research Study (AACR) Yearly Fulfilling 2025, on April 25 – 30 in Chicago. Tempus scientists will certainly display clinical and scientific research study that highlight the transformative effect of AI on oncology therapy an
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/tempus-announces-18-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2025/
